| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
L | | IP | CI | | Levosert | | 119.00 | 145.85 | 10 % | | Intrauterines Wirkstofffreisetzungssystem: Levonorgestrelum 52 mg | Gedeon Richter (Schweiz) AG | B / SL / LPPV | FB | | G |  |
L | | IP | CI | | Levosert One | | 119.00 | 145.85 | 10 % | | Intrauterines Wirkstofffreisetzungssystem: Levonorgestrelum 52 mg | Gedeon Richter (Schweiz) AG | B / SL | FB | | G |  |
L | | IP | CI | | Mirena | piece(s) | 149.08 | 178.55 | 10 % | | Intrauterines Wirkstofffreisetzungssystem: Levonorgestrelum 52 mg | Bayer (Schweiz) AG | B / SL | FB | | G |  |
| | IP | CI | | Kyleena 19.5 mg | | PR | PR | k.A. | | Gestagen abegebendes Intrauterinsystem: Levonorgestrelum 19.5 mg | Bayer (Schweiz) AG | B / LPPV | FB | | G |  |
| | IP | CI | | Jaydess 10 mcg/24 Stunden | piece(s) | PR | PR | k.A. | | Intrauterines Wirkstofffreisetzungssystem: Levonorgestrelum 13.5 mg | Bayer (Schweiz) AG | B / LPPV | FB | | G |  |
|
| | | | | Ringulette 11.7 mg / 2.7 mg | | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | | | | Ringulette 11.7 mg / 2.7 mg | 3 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | | | | Ringulette 11.7 mg / 2.7 mg | 6 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | 3 | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | 3 | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | IP | CI | | Nuvaring | 3 | PR | PR | k.A. | | Vaginalring mit Applikator Btl: 2 Active Agents | APS-Arzneimittel- Parallelimport- Service AG | B | FB | | G |  |
| | | | | MyLoop | | PR | PR | k.A. | | anneau vaginal: 2 Active Agents | Labatec Pharma SA | B | FB | | G |  |
| | | | | MyLoop | 3 | PR | PR | k.A. | | anneau vaginal: 2 Active Agents | Labatec Pharma SA | B | FB | | G |  |
| | IP | CI | CM | Circlet | | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | CM | Circlet | 3 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | | FemiRing | | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Spirig HealthCare AG | B / LPPV | FB | | G |  |
| | IP | CI | | FemiRing | 3 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Spirig HealthCare AG | B / LPPV | FB | | G |  |
| | IP | CI | | FemiRing | 6 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Spirig HealthCare AG | B | FB | | G |  |
| | IP | CI | | NuvaRing | Sachet(s) | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | | NuvaRing | | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | | NuvaRing | 3 Sachet(s) | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | | NuvaRing | 3 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Organon GmbH | B / LPPV | FB | | G |  |
| | IP | CI | | Ornibel | | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Exeltis Suisse SA | B | FB | | G |  |
| | IP | CI | | Ornibel | 3 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Exeltis Suisse SA | B | FB | | G |  |
| | IP | CI | | Ornibel | 6 | PR | PR | k.A. | | Vaginal ring: 2 Active Agents | Exeltis Suisse SA | B | FB | | G |  |
| | IP | CI | | Lina Gynial 0,120 mg / 0,015 mg pro 24 Stunden | | PR | PR | k.A. | | Vaginales Wirkstofffreisetzungssystem: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | IP | CI | | Lina Gynial 0,120 mg / 0,015 mg pro 24 Stunden | 3 | PR | PR | k.A. | | Vaginales Wirkstofffreisetzungssystem: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | IP | CI | | Lina Gynial 0,120 mg / 0,015 mg pro 24 Stunden | 6 | PR | PR | k.A. | | Vaginales Wirkstofffreisetzungssystem: 2 Active Agents | Gynial AG | B | FB | | G |  |
| | IP | CI | | MyLoop | | PR | PR | k.A. | | anneau vaginal: 2 Active Agents | Labatec Pharma SA | B | FB | | G |  |
| | IP | CI | | MyLoop | 3 | PR | PR | k.A. | | anneau vaginal: 2 Active Agents | Labatec Pharma SA | B | FB | | G |  |